What Are Melanotan I & Melanotan II?
Melanotan I and Melanotan II were developed from research involving α-MSH.
Alpha-MSH is a naturally occurring peptide produced from the larger precursor protein proopiomelanocortin, or POMC.
It interacts with melanocortin receptors throughout the body.
These receptors participate in several systems, including:
pigmentation, appetite, energy balance, inflammation, and sexual function.
Researchers became particularly interested in α-MSH because activation of the melanocortin-1 receptor, or MC1R, stimulates melanocytes to produce melanin.
Melanin is the pigment responsible for much of the coloration of human skin and hair and also contributes to the skin’s natural defense against ultraviolet radiation.
Researchers subsequently developed synthetic analogues designed to produce longer-lasting melanocortin activity.
Two of the best known became Melanotan I and Melanotan II.
What Is Melanotan I?
Melanotan I is a synthetic analogue of α-MSH.
It was designed to produce longer-lasting melanocortin activity than naturally occurring α-MSH.
Its research centered primarily on stimulating eumelanin production and increasing pigmentation.
The development of MT-1 ultimately became particularly important because a pharmaceutical version of this molecule was developed as afamelanotide.
Afamelanotide is now an FDA-approved medication.
That gives MT-1 a very different scientific and regulatory history from many peptides commonly encountered in research markets.
What Is Melanotan II?
Melanotan II, commonly abbreviated MT-2, is another synthetic melanocortin analogue.
It was developed during research seeking potent and durable α-MSH-like compounds.
MT-2 stimulates multiple melanocortin receptors rather than acting exclusively on pigmentation pathways.
That broader activity explains why researchers observed effects beyond tanning.
Research involving MT-2 eventually contributed to discoveries involving appetite and sexual function as well as pigmentation.
This makes MT-2 scientifically fascinating, but also pharmacologically less targeted than MT-1-derived afamelanotide.
How Do They Work?
Both compounds interact with the melanocortin receptor system.
Five major melanocortin receptors are known:
MC1R, MC2R, MC3R, MC4R, and MC5R.
MC1R is especially important in melanocytes.
When MC1R is activated, melanocytes increase signaling involved in production of eumelanin, the brown-black form of melanin.
This is why melanocortin agonists can darken skin pigmentation.
But melanocortin receptors also exist outside the skin.
MC3R and MC4R, for example, participate in central nervous-system pathways involving appetite, energy balance, and sexual behavior.
That broader receptor biology becomes particularly important when discussing MT-2.
Melanin & Pigmentation Research
Pigmentation is the most obvious area of Melanotan research.
Melanocytes manufacture melanin and transfer pigment-containing structures to surrounding skin cells.
Melanin absorbs and disperses portions of ultraviolet radiation.
Activation of MC1R favors production of darker eumelanin rather than the lighter pheomelanin pathway.
Researchers therefore investigated whether melanocortin analogues could increase pigmentation without relying entirely on UV exposure.
Human studies demonstrated that melanocortin analogues can indeed increase skin pigmentation.
This research eventually progressed far enough with afamelanotide to produce an approved medical therapy.
Melanotan I & Afamelanotide
The MT-1 story is particularly important because it demonstrates that melanocortin peptide research produced an actual medicine.
Afamelanotide is a synthetic analogue of α-MSH and is essentially the pharmaceutical development of the compound historically known as Melanotan I.
In 2019, the FDA approved afamelanotide under the brand name Scenesse.
Its indication is increasing pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria, or EPP.
EPP causes extreme sensitivity to visible light.
Afamelanotide increases eumelanin production, helping provide greater photoprotection.
This is strong evidence that manipulating melanocortin pigmentation pathways can have legitimate therapeutic value.
Photoprotection Research
Melanin does more than change skin color.
Eumelanin can absorb ultraviolet radiation and reduce some of the oxidative damage produced by UV exposure.
This has made melanocortin signaling interesting in photoprotection research.
However, increased pigmentation should not be interpreted as complete protection against ultraviolet damage.
A tan does not eliminate the risk of sunburn, DNA damage, premature skin aging, or skin cancer.
The scientific interest lies in understanding whether increasing eumelanin can provide an additional layer of biological photoprotection.
MT-1 vs. MT-2
Although the names sound almost interchangeable, MT-1 and MT-2 should not be treated as the same compound.
MT-1 is closely associated with the development of afamelanotide and has a more focused pigmentation-related history.
MT-2 interacts more broadly with the melanocortin system.
That broader activity contributes to effects involving:
pigmentation, appetite, nausea, spontaneous erections, sexual arousal, and other central nervous-system effects.
In simple terms:
MT-1 is the more pigmentation-focused branch of melanocortin research.
MT-2 is the broader melanocortin-receptor research compound.
Appetite Research
One of the most interesting effects of MT-2 involves appetite.
The central melanocortin system plays an important role in regulating food intake and energy balance.
MC4R signaling in particular is strongly connected with appetite regulation.
Experimental research with melanocortin agonists has demonstrated reductions in food intake.
This helped establish melanocortin receptors as important metabolic targets.
Today, the melanocortin system remains an active area of obesity and metabolic research.
MT-2 itself has not become an approved weight-loss medication, but its research contributed to our understanding of these pathways.
Sexual-Function Research
MT-2 produced one of the more unexpected discoveries in peptide pharmacology.
During early human research, investigators observed spontaneous erections and changes in sexual arousal.
Rather than being dismissed as an irrelevant side effect, the finding led researchers to investigate melanocortin signaling in sexual function.
That research eventually contributed to development of another melanocortin drug: bremelanotide.
Bremelanotide, also known as PT-141, was developed from MT-2-related research and later became an FDA-approved medication for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women.
So MT-2 research ultimately helped uncover an entirely different therapeutic pathway beyond pigmentation.
MT-2 & PT-141
PT-141, or bremelanotide, is structurally and historically related to MT-2.
Researchers were interested in separating MT-2’s sexual effects from its pigmentation effects.
Bremelanotide was developed specifically around melanocortin pathways involved in sexual desire rather than tanning.
That development history is a great example of how peptide research evolves.
An unexpected observation from one experimental compound can reveal a biological pathway that eventually produces a completely different medication.
Skin Research
Melanocortin biology extends beyond pigmentation.
Alpha-MSH and melanocortin receptors participate in inflammatory signaling, oxidative stress, immune regulation, and skin homeostasis.
Researchers therefore continue investigating melanocortin pathways in dermatology.
This includes research involving:
pigmentation disorders, photoprotection, inflammatory skin biology, oxidative stress, and UV-related cellular damage.
MT-1-derived afamelanotide currently provides the clearest example of this research translating successfully into clinical medicine.
Freckles & Moles
Melanocortin stimulation can darken existing pigmented areas.
People exposed to unapproved Melanotan products have reported darkening of freckles and existing moles, as well as the appearance or increased visibility of pigmented lesions.
This is particularly important with MT-2 because products sold outside regulated pharmaceutical channels are sometimes marketed specifically for cosmetic tanning.
Any rapidly changing, irregular, bleeding, or otherwise concerning pigmented lesion warrants medical evaluation rather than assuming the change is simply cosmetic.
Nausea & Appetite Changes
Because MT-2 activates melanocortin pathways outside the skin, its effects can extend well beyond pigmentation.
Nausea is one of the commonly reported effects associated with melanocortin agonism.
Reduced appetite can also occur.
Flushing and changes in sexual arousal have been reported as well.
These effects make sense pharmacologically because MT-2 is interacting with a receptor system that regulates multiple physiological processes.
This broader activity is one of the biggest differences between MT-2 and a targeted cosmetic tanning ingredient.
Evidence Snapshot
Melanocortin biology: Strong. The melanocortin receptor system is well characterized and plays established roles in pigmentation, metabolism, and other physiological functions.
Pigmentation evidence: Strong. Human research demonstrates that melanocortin agonism can increase pigmentation.
MT-1 / afamelanotide: Strong human clinical evidence for its approved indication. Afamelanotide progressed through clinical development and received FDA approval.
MT-2 pigmentation: Human evidence exists demonstrating biological activity, but MT-2 has not become an approved tanning medication.
Appetite research: Strong mechanistic basis with meaningful experimental evidence connecting central melanocortin signaling with food intake.
Sexual-function research: Particularly important historically. MT-2-related findings helped lead to development of bremelanotide.
Cosmetic tanning use of unapproved MT-2 products: Not equivalent to an approved therapeutic use.
What Do We Know?
The core biology behind Melanotan compounds is well established.
Alpha-MSH regulates melanocortin receptors.
MC1R activation influences melanin production.
Synthetic melanocortin analogues can increase pigmentation in humans.
We also know the melanocortin system reaches far beyond skin color.
It participates in appetite, energy regulation, inflammation, and sexual function.
Most importantly, research originating from these compounds has already produced two notable pharmaceutical developments:
afamelanotide from the MT-1 branch and bremelanotide from MT-2-related research.
That makes the Melanotan story one of the more interesting examples of experimental peptide research translating into conventional medicine.
What Are Researchers Still Trying to Determine?
Researchers continue investigating how selectively different melanocortin receptors can be targeted.
That selectivity matters enormously.
A compound designed for pigmentation ideally would not produce unnecessary effects on appetite or sexual pathways.
Likewise, a compound designed for metabolic or sexual-function research may not need to stimulate pigmentation.
Researchers are also studying melanocortin signaling in:
obesity, inflammatory disease, pigmentation disorders, photoprotection, genetic MC4R disorders, skin biology, and neuroendocrine regulation.
The challenge is increasingly not whether melanocortin signaling works.
It is learning how to target the right melanocortin receptor in the right tissue for the right purpose.
Research & Regulatory Status
The regulatory distinction between these compounds is especially important.
Afamelanotide, the pharmaceutical development associated with Melanotan I, is FDA approved as Scenesse for a specific medical indication involving erythropoietic protoporphyria.
That does not mean generic research-market “MT-1” products are FDA-approved Scenesse.
The approved product has controlled manufacturing, dosing, formulation, and clinical oversight.
Melanotan II is not FDA approved as a tanning medication or general therapeutic drug.
Products sold online as MT-2 therefore should not be confused with an FDA-approved melanocortin medication.
Your Pep Resource Takeaway
Melanotan I and Melanotan II helped open an entire chapter of melanocortin research.
What began largely as an attempt to manipulate pigmentation revealed a signaling network involved in skin pigmentation, photoprotection, appetite, metabolism, inflammation, and sexual function.
MT-1 ultimately led to afamelanotide, an FDA-approved treatment for EPP.
MT-2 produced unexpected observations involving sexual function that contributed to development of bremelanotide.
That makes these compounds scientifically significant far beyond their reputation as “tanning peptides.”
MT-2 itself remains experimental and carries substantially more uncertainty than an approved pharmaceutical product.
But from a research perspective, the Melanotan story demonstrates exactly why peptide science can be so interesting: studying one biological effect can reveal entirely new pathways and eventually lead to therapies researchers were not originally looking for.
Research Areas / Search Keywords
Melanotan, Melanotan I, Melanotan 1, MT-1, MT1, Melanotan II, Melanotan 2, MT-2, MT2, tanning peptide, tanning research, pigmentation peptide, melanin peptide, melanin production, melanogenesis, eumelanin, skin pigmentation, alpha-MSH, α-MSH, alpha melanocyte stimulating hormone, melanocortin, melanocortin receptor, MC1R, MC3R, MC4R, MC5R, POMC, melanocytes, afamelanotide, Scenesse, afamelanotide peptide, erythropoietic protoporphyria, EPP, phototoxicity, photoprotection, UV research, sunlight sensitivity, skin research, pigmentation disorder research, freckles, mole darkening, appetite research, appetite suppression research, energy balance, metabolic research, melanocortin metabolism, sexual function research, sexual arousal, spontaneous erection, PT-141, bremelanotide, MT-2 PT-141, melanocortin sexual function, inflammatory skin research, oxidative stress, neuroendocrine research, experimental peptide, research peptide, peptide science.
Educational Disclaimer
This profile is provided for educational and research-information purposes only. Discussion of pigmentation, appetite, sexual function, photoprotection, or other melanocortin research does not establish that unapproved Melanotan products are safe or effective for cosmetic tanning or another use. Afamelanotide is an FDA-approved medication for a specific indication, but research-market MT-1 products should not be assumed to be equivalent to the approved pharmaceutical product. Melanotan II is not an FDA-approved tanning medication.